-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics, Maintains $25 Price Target

Benzinga·05/14/2025 14:25:06
Listen to the news
Cantor Fitzgerald analyst Kristen Kluska reiterates Zevra Therapeutics (NASDAQ:ZVRA) with a Overweight and maintains $25 price target.